Session: SAT 723-745-Lipids: Fatty Liver Disease & Lipodystrophies
Poster Board SAT-732
Methods: 102 HIV+ subjects and 41 non-HIV controls without clinical CVD underwent metabolic/immune phenotyping and coronary CT angiography (for assessment of subclinical atherosclerosis). HRA was determined using a validated fluorometric biochemical assay measuring the effect of purified HDL from subject cryopreserved serum on the rate of oxidation of dihydrorhodamine 123 (DOR). The DOR value for 1.25 ug of HDL cholesterol from each subject (measured in fluorescence units/minute) was normalized to the DOR of HDL from pooled serum of healthy blood bank donors. The ratio DORsubject/DORpooled was used as a measure of HRA, with higher HRA suggesting dysfunctional HDL.
Results: The HIV+ and non-HIV groups were well-matched on traditional CVD risk factors. 95% of HIV+ subjects were on ART. HRA was significantly higher in the HIV+ group versus the non-HIV group (1.4 ± 0.01 vs. 1.3 ± 0.01, p=0.03). Among the entire cohort, HRA correlated inversely with log-transformed HDL levels (r=-0.31, p=0.0002). HRA among HIV+ subjects correlated negatively with log-transformed adiponectin levels (r=-0.28, p=0.006) and positively with log-transformed levels of the macrophage activation marker soluble CD163 (r=0.24, p=0.02). With respect to cardiometabolic risk parameters, HRA associated positively with log HOMA-IR among non-diabetic HIV+ subjects (r=0.34, p=0.005) and with the percentage of non-calcified coronary plaque among all HIV+ subjects (r=0.29, p=0.03).
Conclusions: These data are the first to show increased HRA among HIV+ subjects on ART vs. matched non-HIV subjects with comparable HDL levels. Among HIV+ subjects, HRA is associated with measures of immune and cardiometabolic dysregulation, including levels of sCD163, log HOMA-IR, and percent non-calcified coronary plaque. Further studies are needed to confirm the utility of HRA as a biomarker for cardiometabolic risk among HIV+ patients.
Disclosure: SG: Principal Investigator, Bristol-Myers Squibb. Nothing to Disclose: MVZ, TK, MF, JL, SA, BW, EM, NH, OOY, JSC
*Please take note of The Endocrine Society's News Embargo Policy at http://www.endo-society.org/endo2013/media.cfm
See more of: Abstracts - Orals, Featured Poster Presentations, and Posters